Cargando…
PSUN305 A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Obese or Overweight Subjects with Co-morbidities
HM15136 is a novel long-acting glucagon analogue with an extended half-life. In vivo efficacy studies of HM15136 in animal models showed its therapeutic potential in obesity, and treatment requiring hypoglycemia. We enrolled an obese and overweight subjects without diabetes (study Part 1) and with d...
Autores principales: | Shin, Wonjung, Choi, JaeDuk, Yun, Hyori, Han, OakPil, Cho, Hyungjin, Hompesch, Marcus, Baek, Seungjae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625659/ http://dx.doi.org/10.1210/jendso/bvac150.851 |
Ejemplares similares
-
SAT149 In Vitro Characterization Of A Novel Long-acting Glucagon Analog (HM15136) And Its Potential Effect In Animal Models Of Chronic Hypoglycemic Diseases
por: Kim, Jung Kuk, et al.
Publicado: (2023) -
PSUN140 “Awakening of the Beta Cell(©)”
por: Jasper, Josephine, et al.
Publicado: (2022) -
PSUN274 Chlorthalidone-Induced Diabetic Ketoacidosis.
por: Zafar, Rafia, et al.
Publicado: (2022) -
PSUN254 Hirata's Disease - An Unexpected Surprise
por: Al-Bahadili, Huda, et al.
Publicado: (2022) -
RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)